Front Page News
Nevada Starts Screening for SMA – Only One State Remains!
Nevada has become the 49th state to begin screening for spinal muscular atrophy (SMA). Nevada State Public Health Laboratory officials confirmed with Cure SMA that […]
Read More ›Analysis: Cure SMA’s Risk/Benefit Survey
One of Cure SMA’s top priorities is to relay the SMA community’s treatment experiences and preferences to the United States Food and Drug Administration (FDA). […]
Read More ›Winter Immunization Recommendations
Cooler weather serves as a reminder to explore how to keep ourselves healthy through the cold and flu season. What you can do to protect […]
Read More ›Novartis Gene Therapies Releases SMA Community Statement
This week, Novartis Gene Therapies released an SMA community statement detailing the progress on enrollment for both STEER and STRENGTH clinical trials, their investigational intrathecal […]
Read More ›Genentech Releases SMA Community Letter with Evrysdi (risdiplam) Updates
Our partners at Genentech recently provided an SMA Community Letter regarding Evrysdi® (risdiplam) and their clinical development program. Visit this link to learn more.
Read More ›Cure SMA Featured in the NFL’s My Cause My Cleats
Cure SMA is thrilled to have recently been featured in the National Football League’s (NFL) My Cause My Cleats campaign. Through this fantastic initiative, players […]
Read More ›Administration Officials & Members of Congress Highlight SMA Community Advocacy at 12th Annual Hope on the Hill Washington, D.C. Event
Two high-ranking Administration officials and several Members of Congress from key congressional committees participated in Cure SMA’s November 29th Hope on the Hill dinner and […]
Read More ›Sweet Success: Baking a Difference Returns for a Second Year
Breaking and Baking News! Get ready to dust off those aprons and preheat those ovens because Baking a Difference is back and better than […]
Read More ›Biogen Shares DEVOTE and RESPOND Study Updates
Biogen recently shared that they have completed enrollment in the global DEVOTE and RESPOND clinical studies. Check out the full SMA Community Statement here.
Read More ›Genentech Shares 1-Year Primary Analysis from RAINBOWFISH
Last week, Genentech, a member of the Roche Group, presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and […]
Read More ›